Epoch 33 - Why Merck is Paying a Small Biotech $3.5B for Access to Circular RNA Technology

A Case Study of the ORNA/Merck Deal

Aug 21, 2022

∙ Paid

Welcome to the 57 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 727 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we witnessed what we would consider an oversized outlier deal coming from…

Keep reading with a 7-day free trial

Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.